Education about Non-Alcoholic Steatohepatitis (NASH) and the Role of PPAR Agonists
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system and thus improving the lives of millions of patients worldwide.
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and Dr. Scott Friedman talks about HCC pathogenesis in NASH and the impact of fibrosis. This Dr. Kris Kowdley explains the natural history and clinical outcomes in adults with non -alcoholic Prof. Luisa Vonghia (Belgium) explores the role of fatty liver disease and metabolic comorbidities in 
How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient
HCC Pathogenesis in NASH and the Impact of Fibrosis
Natural history & clinical outcomes in adults with NAFLD
The role of fatty liver disease and metabolic comorbidities in the progression on liver diseases
Dr. Castera discusses how clinicians can integrate NASH assessment and management into the care of diabetic patients in order to Patients and physicians have to know that NASH increases the risk to develop cancers. Specific surveillance has to be implemented The best treatment for NASH still remains as caloric intake reduction, weight loss, exercise and no heavy alcohol consumption, but Discover all about NASH, NAFLD PPAR agonists ⟶
How to integrate NASH assessment and management into the care of diabetic patient
Cancers and NASH
NASH Management in 2022
Vigorous physical activity and reduced all-cause mortality: a significant association?
Currently, the most effective treatment for non-alcoholic fatty liver disease (NAFLD) is diet and exercise. Weight loss of 5% achieved through lifestyle interventions has been associated with the reversal of steatosis, and a 10% weight reduction has been linked to the reversal of fibrosis. Physical activity (PA) has been hypothesised to reduce the accumulation of intrahepatic triglycerides contributing to NAFLD progression.
The impact of exercise on hepatic liver droplets for the prevention and treatment of NAFLD
Lipid droplets (LDs) are lipid-rich and dynamic organelles which undergo cycles of biogenesis (triacylglycerol synthesis, as well as LD growth, budding, and expansion) and degradation (lipophagy). Many studies have highlighted the causative role of abnormal LD accumulation in the development of non-alcoholic fatty liver disease (NAFLD). Furthermore, while the positive impact of physical activity on NAFLD has been widely studied, its effect on LD dynamics remains unclarified.
Ultrasound-based methods for the diagnosis and staging of liver steatosis
Research in recent years has documented the rise of quantitative ultrasound-based examinations (qnUS) for the assessment of liver steatosis. qnUS of interest include continuous attenuation parameters (CAP), backscatter coefficients, and ultrasound envelope statistic parametric imaging. Despite the clear financial and patient-centric benefits of such non-invasive tools, their reliability in defining both the presence and degree of liver steatosis remains unclear.
Transitioning from NAFLD to MAFLD: criticism and concerns
The term metabolic dysfunction-associated fatty liver disease (MAFLD) has recently been
suggested as an alternative to non-alcoholic fatty liver disease (NAFLD). Unlike NAFLD,
MAFLD’s diagnosis is based on the active identification of NAFLD-associated metabolic abnormalities. Many researchers agree that MAFLD adequately captures the systemic factors and upstream drivers of the disease, with a significant proportion concluding that it does so better than the original NAFLD definition.
New this week!
How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and management into the care of diabetic patients in order to provide a holistic
EDITOR OF THE MONTH!
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of …
Latest Research toward the treatment of NASH disease
Knowledge is crucial for healthcare professionals to manage and diagnose patients with NASH and NAFLD. Over the years, we have been increasingly communicating the results achieved by research, showcasing the latest on therapy to diagnosis and management.
LATEST SCIENTIFIC ADVANCES IN NASH, NAFLD & PPAR AGONISTS
NASH Treatment in 2022: Review of Current and Future Therapies for Non-Alcoholic Steatohepatitis
Prof. Stephen Harrison (USA) reviews current and future therapies for Non-Alcoholic Steatohepatitis (NASH). After a
Psychological aspects of health behaviours in NAFLD non-alcoholic fatty liver disease
Prof. Maya Balakrishnan (USA) discusses the importance of the behavioural psychology in the field of
NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in
Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)
This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered
GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3)
In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty
Getting to the heart of nafld/nash – the cvd perspective (part 2)
Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic
UPCOMING NASH EVENTS
AASLD THE LIVER MEETING
COMMENTED ARTICLES
Vigorous physical activity and reduced all-cause mortality: a significant association?
Currently, the most effective treatment for non-alcoholic fatty liver disease (NAFLD) is diet and exercise. Weight loss of 5% achieved through lifestyle interventions has been associated with the reversal of
The impact of exercise on hepatic liver droplets for the prevention and treatment of NAFLD
Lipid droplets (LDs) are lipid-rich and dynamic organelles which undergo cycles of biogenesis (triacylglycerol synthesis, as well as LD growth, budding, and expansion) and degradation (lipophagy). Many studies have highlighted
CATEGORIES
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
Latest articles from PubMed
- Mechanism of action of <em>Orthosiphon stamineus</em> against non-alcoholic fatty liver disease: Insights from systems pharmacology and molecular docking approaches December 5, 2022
- NAFLD, MAFLD and obesity: brothers in arms? December 5, 2022
- NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change December 5, 2022
- Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio has a non-linear association with non-alcoholic fatty liver disease: A secondary prospective cohort study in non-obese Chinese adults December 5, 2022
- Elevated serum levels of diamine oxidase, D-lactate and lipopolysaccharides are associated with metabolic-associated fatty liver disease December 5, 2022
- Non-alcoholic fatty liver disease and type 2 diabetes mellitus: general approaches to the choice of therapy December 5, 2022
- Blood endotoxin levels as biomarker of non-alcoholic fatty liver disease: a systematic review and meta-analysis December 5, 2022
- Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications December 5, 2022
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.